Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 7, 2009; 15(29): 3636-3642
Published online Aug 7, 2009. doi: 10.3748/wjg.15.3636
Table 1 Baseline patient characteristics n (%)
Imipramine (n = 59)Placebo (n = 48)
Mean age (yr)42.6 ± 12.445.3 ± 13.8
Male sex33 (55.9)29 (60.4)
Type of recruitment38 (64.4) referrals29 (60.4) referrals
Bloating/distention57 (96.6)46 (95.8)
Abdominal pain58 (98.3)47 (97.9)
Flatulence45 (76.3)40 (83.3)
Constipation17 (28.8)15 (31.3)
Diarrhea11 (18.6)7 (14.6)
Mixed pattern14 (23.7)15 (31.3)
Mean baseline SF-36 score98.6 ± 21.3102.8 ± 16.6
Table 2 Reason for dropout in both study groups n (%)
Imipramine (n = 59)Placebo (n = 48)P-value
Total dropouts28 (47.5)23 (47.9)NS
Premature withdrawal8 (13.6)14 (29.2)< 0.05
Lost to follow-up3 (5.1)3 (6.3)NS
Protocol violation30NS
Side effects14 (23.7)6 (12.5)0.094
Table 3 Side effect leading to dropout in the imipramine treatment group
Side effectNumber of patients (n = 14)
Sleep disturbance3
Urologic symptoms2
Palpitations2
Anxiety1
Dry mouth1
Dizziness3
Flushing & sweating1
Constipation1